Data from Clinicaltrials.gov - Curated by Toby Galbraith - Last updated 17 February 2017

The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis.

purpose

The purpose of this study is to evaluate the serum concentration of ixekizumab after administration using either prefilled syringe or auto-injector in participants with moderate to severe plaque psoriasis. Treatment period is followed by 40 weeks optional safety extension.

 

Category Value
Date last updated at source 13-Sep-16
Study type(s) Interventional
Expected enrolment 204
Study start date 13-Mar-13
Estimated primary completion date 01-May-15

View full details

Comments

You will need to login, to leave a comment.

epgonline.org is not monitored for collection of adverse event reports. Any adverse events should be reported to your national reporting agency and/or the manufacturer.

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

IL-17A in Psoriasis

Experts discuss new targeted therapies for psoriasis at the European Association of Dermatology and Venereology (EADV) Congress 2015

Visit IL-17A in Psoriasis


Psoriasis

See information on psoriasis pathophysiology, signs and symptoms, comorbidities, treatment options, and more

Visit Psoriasis


Related Content